TET2 and cyclic hematopoiesis: At baseline, CH occurred in 35.5% patients with <i>DNMT3A</i> (<i>N</i> = 41, 16.9%) and <i>TET2</i> (<i>N</i> = 29, 12.0%) being the most frequently mutated genes.